Source:http://linkedlifedata.com/resource/pubmed/id/20647254
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
2010-10-26
|
pubmed:abstractText |
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, which, despite the advances in immunosuppressive medical therapies, remains potentially fatal in some patients, especially in treatment-refractory patients. This study found that transplantation of umbilical cord mesenchymal stem cells (UC-MSCs) has the same therapeutic effect as transplantation of bone marrow mesenchymal stem cells (BM-MSCs), which has been reported to be efficient in treating SLE-related symptoms in MRL/lpr mice. Multi-treatment (at the 18th, 19th, and 20th weeks of age) of 1 × 10(6) UC-MSCs was able to decrease the levels of 24-h proteinuria, serum creatinine, and anti-double-stranded DNA (dsDNA) antibody, and the extent of renal injury such as crescent formation in MRL/lpr mice. A lower, but still significant, reduction in these parameters was also observed in mice receiving a single dose of UC-MSCs (at the 18th week). UC-MSCs treatment also inhibited expression of monocyte chemotactic protein-1 (MCP-1) and high-mobility group box 1 (HMGB-1) expression in a similar fashion. UC-MSCs labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) were found in the lungs and kidneys 1 week post infusion. In addition, after 11 weeks post UC-MSCs infusion, human cells were found in kidney of UC-MSCs-treated mice. These findings indicated that UC-MSCs transplantation might be a potentially promising approach in the treatment of lupus nephritis, possibly by inhibiting MCP-1 and HMGB-1 production.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1477-0962
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1502-14
|
pubmed:meshHeading |
pubmed-meshheading:20647254-Animals,
pubmed-meshheading:20647254-Antibodies, Antinuclear,
pubmed-meshheading:20647254-Bone Marrow Cells,
pubmed-meshheading:20647254-Bone Marrow Transplantation,
pubmed-meshheading:20647254-Chemokine CCL2,
pubmed-meshheading:20647254-Creatinine,
pubmed-meshheading:20647254-Female,
pubmed-meshheading:20647254-Gene Expression Regulation,
pubmed-meshheading:20647254-HMGB1 Protein,
pubmed-meshheading:20647254-Humans,
pubmed-meshheading:20647254-Lupus Nephritis,
pubmed-meshheading:20647254-Mesenchymal Stem Cell Transplantation,
pubmed-meshheading:20647254-Mice,
pubmed-meshheading:20647254-Mice, Inbred MRL lpr,
pubmed-meshheading:20647254-Proteinuria,
pubmed-meshheading:20647254-Umbilical Cord
|
pubmed:year |
2010
|
pubmed:articleTitle |
Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice.
|
pubmed:affiliation |
Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|